PHARMACOLOGICAL ANTAGONISM AND GENETIC MANIPULATION OF CANNABINOID CB1 RECEPTORS IN THE AMYGDALA TO REDUCE PROTRACTED ETHANOL CONSUMPTION
PHARMACOLOGICAL ANTAGONISM AND GENETIC MANIPULATION OF CANNABINOID CB1 RECEPTORS IN THE AMYGDALA TO REDUCE PROTRACTED ETHANOL CONSUMPTION
批准号:
10159728
负责人:
Russell Scott Dulman
金额:
$5.1万
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
已结题
起止时间:
2020-04-15 至 2023-04-14
关键词:
AcetylationAgonistAlcohol consumptionAlcoholsAmygdaloid structureAnimalsBehaviorBehavioralBiochemicalBrainCNR1 geneCannabinoidsCell NucleusChronicComplexConsumptionControl GroupsDataEndocannabinoidsEnzymesEpigenetic ProcessEthanolFemaleFunctional disorderGene ExpressionGeneticHealthHeroinHourIn Situ HybridizationInfusion proceduresInjectionsKDM1A geneLocationMeasuresMediatingMental disordersMessenger RNAMetabolicMethylationModificationMolecularMusNeurobiologyNicotineOutputPathway interactionsPharmaceutical PreparationsPharmacologyPharmacotherapyRNARecording of previous eventsRegulationRodentSelf AdministrationSignal TransductionSmall Interfering RNASystemTestingTranslatingWateraddictionalcohol abuse therapyalcohol effectalcohol exposurealcohol use disorderbasecannabinoid receptorcannabinoid receptor antagonistchronic alcohol ingestiondensitydrinkingdrinking behaviorendocannabinoid signalingendogenous cannabinoid systemepigenetic regulationexperimental studygenetic manipulationhistone acetyltransferasehistone modificationimprovedinnovationintraperitonealknock-downmalenegative affectnovelpre-clinicalpromoterreceptorrimonabantsex
中文摘要
项目摘要/摘要
酒精使用障碍(AUD)是一个普遍存在的问题,具有重大的健康和社会意义
造成的后果和改进治疗的需要。内源性大麻素系统是一种
新的AUD药物治疗有希望的靶点。长期饮用乙醇会导致
负性情绪状态下杏仁核的分子和表观遗传学改变
上瘾。杏仁核有高密度的大麻素CB1受体。而大麻素
拮抗剂减少饮酒,他们改变分子和表观遗传学变化的能力
杏仁核仍未被发现。此外,中性大麻素受体拮抗剂具有
与利莫那班等较老的反向激动剂相比,精神负担更小。本项目探索
大麻素受体的操纵将为一种新的AUD药物治疗和
描述内源性大麻素系统在饮酒行为中的表观遗传调控。
尽管有适应症,中性大麻素受体拮抗剂可减少药物和酒精
消费,但不太清楚长期饮酒对表观遗传学的影响
内源性大麻素系统或CB1受体如何在特定的成瘾相关脑回路中
延伸的杏仁核调节饮酒行为。这一提议是基于这样的假设
CB1受体系统的调节可以减少不断升级的酒精饮酒和
逆转酒精诱导的脑内基因表达和组蛋白修饰的变化
杏仁核。我们将通过评估AM4113对饮酒行为的影响和
杏仁核内大麻素系统基因表达的生化变化及整体和
20%乙醇间歇作用后特异性Cnr1(CB1mRNA)组蛋白修饰
喝酒。我们将进一步测试中央核和基底外侧核中Cnr1基因敲除的效果
杏仁核对长时间饮酒行为的影响
杏仁核足以产生同样的下游行为和生化效应。总的来说,
这些实验将进一步加深对内源性大麻素系统及其
长期饮酒过程中的表观遗传调控,同时提供关键的临床前数据
翻译内源性大麻素靶向治疗AUD。
英文摘要
Project Summary/Abstract
Alcohol Use Disorder (AUD) is a widespread problem with significant health and societal
consequences and a need for improved treatments. The endogenous cannabinoid system is a
promising target for new AUD pharmacotherapy. Prolonged ethanol consumption leads to
molecular and epigenetic changes in the amygdala underlying the negative affective state in
addiction. The amygdala has a high density of cannabinoid CB1 receptors. While cannabinoid
antagonists reduce ethanol drinking, their ability to alter molecular and epigenetic changes in the
amygdala remains unexplored. Furthermore, neutral cannabinoid receptor antagonists possess
less psychiatric liabilities than older inverse agonists such as rimonabant. This project exploring
cannabinoid receptor manipulations will provide evidence for a novel AUD pharmacotherapy and
characterize the epigenetic regulation of the endocannabinoid system in drinking behaviors.
Despite indications neutral cannabinoid receptor antagonism reduces drug and ethanol
consumption, it is less clear how chronic ethanol drinking epigenetically impacts the
endocannabinoid system or how CB1 receptors in specific addiction-related brain circuits such as
the extended amygdala regulate drinking behaviors. This proposal is based on the hypothesis
that modulation of the CB1 receptor system can reduce escalated ethanol drinking and
reverse alcohol-induced changes in gene expression and histone modifications in the
amygdala. We will test this hypothesis by assessing AM4113 effects on drinking behavior and
biochemical changes in amygdalar endocannabinoid system gene expression and global and
specific Cnr1 (CB1 mRNA) histone modifications following intermittent-access 20% ethanol
drinking. We will further test the effect of Cnr1 knockdown within the central and basolateral nuclei
of the amygdala on protracted drinking behavior to specifically localize sub-regions of the
amygdala as sufficient for these same downstream behavioral and biochemical effects. Overall,
these experiments will further the understanding of the endocannabinoid system and its
epigenetic regulation during protracted ethanol drinking while providing key preclinical data for
translating endocannabinoid-targeted treatments for AUD.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
PHARMACOLOGICAL ANTAGONISM AND GENETIC MANIPULATION OF CANNABINOID CB1 RECEPTORS IN THE AMYGDALA TO REDUCE PROTRACTED ETHANOL CONSUMPTION
-
批准号:10380565
-
项目类别:
-
资助金额:$5.18万
-
财政年份:2020
-
负责人:Russell Scott Dulman
-
依托单位:
国内基金
海外基金
Agonist-GPR119-Gs复合物的结构生物学研究
-
批准号:32000851
-
项目类别:青年科学基金项目
-
资助金额:24.0万元
-
批准年份:2020
-
负责人:乔安娜
-
依托单位: